# The Safety and Efficacy of CD38 Monoclonal Antibody Monotherapy for CaAMR in Renal Transplantation

> **NCT05913596** · NA · UNKNOWN · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 15 (estimated)

## Conditions studied

- Antibody-mediated Rejection
- Kidney Tranplant

## Interventions

- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT05913596
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-23
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-08-30
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2023-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05913596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05913596, "The Safety and Efficacy of CD38 Monoclonal Antibody Monotherapy for CaAMR in Renal Transplantation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05913596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*